Antisoma Update -- Progress on Partnering and Development of AS1404
August 15, 2006 02:23 ET
|
Antisoma plc
LONDON, Aug. 15, 2006 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) (Pink Sheets:AIOAF) today provides an update on its commercialisation strategy for AS1404 and progress in the drug's...
Extended Follow-up of Renal Cancer Patients Provides New Support for Antisoma's AS1411
November 16, 2005 02:09 ET
|
Antisoma plc
LONDON and PHILADELPHIA, Nov. 16, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) announces the presentation of long-term follow-up data from the phase I trial of its aptamer drug...
Antisoma's AS1404 Whips Up a Cytokine Storm to Attack Cancer
November 15, 2005 02:09 ET
|
Antisoma plc
LONDON and PHILADELPHIA, Nov. 15, 2005 (PRIMEZONE) -- A presentation today at the AACR-NCI-EORTC meeting in Philadelphia offers new insights into the mechanism of action of Antisoma's phase II cancer...
Antisoma to Present at the SG Cowen and Rodman & Renshaw Healthcare Conferences
November 02, 2005 07:37 ET
|
Antisoma plc
LONDON, Nov. 2, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) today announces that it will be presenting at the upcoming SG Cowen and Rodman & Renshaw healthcare conferences....
Antisoma Presents AS1404 Data at ECCO -- the European Cancer Conference
November 01, 2005 02:08 ET
|
Antisoma plc
LONDON and PARIS, Nov. 1, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) will today present data on its most advanced drug, AS1404, at ECCO -- the European Cancer Conference. AS1404...
Antisoma Announces Promising Preliminary Phase II Data for AS1404 in Lung Cancer
October 17, 2005 02:19 ET
|
Antisoma plc
LONDON, Oct. 17, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) today announces preliminary findings from an ongoing phase II trial of AS1404 in lung cancer. With initial data...
Antisoma's Preliminary Results for the Year-Ended 30 June 2005
September 15, 2005 03:24 ET
|
Antisoma plc
LONDON, Sept. 15, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) today announces its preliminary results for the year ended 30 June 2005.
Highlights of 2004/2005
Advances...
First Patient Treated in Extended Phase I Trial of Antisoma's AS1411
September 06, 2005 02:09 ET
|
Antisoma plc
LONDON, Sept. 6, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has reopened a U.S. phase I trial of its aptamer drug AS1411 following the presentation of promising...
Antisoma's AS1404 Lung Cancer Study Reaches Recruitment Target
September 01, 2005 02:07 ET
|
Antisoma plc
LONDON, Sept. 1, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has reached the patient recruitment target in its phase II trial of AS1404 in non-small cell lung...
Antisoma Granted U.S. Orphan Drug Status for AS1411 in Renal Cancer
August 17, 2005 02:21 ET
|
Antisoma plc
LONDON, Aug. 17, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) has received notification from the U.S. Food and Drug Administration (FDA) that its aptamer drug AS1411 has been granted...